{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T16:07:57Z","timestamp":1781366877219,"version":"3.54.1"},"reference-count":114,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["dldjournalonline.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.dld.2018.04.020","type":"journal-article","created":{"date-parts":[[2018,4,27]],"date-time":"2018-04-27T17:21:29Z","timestamp":1524849689000},"page":"741-749","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases"],"prefix":"10.1016","volume":"50","author":[{"given":"Jasmohan S.","family":"Bajaj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Barbara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert L.","family":"DuPont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Mearin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gasbarrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Tack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2018.04.020_bib0005","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/978-3-642-38007-5_22","article-title":"Gut microbes, diet, and cancer","volume":"159","author":"Hullar","year":"2014","journal-title":"Cancer Treat Res"},{"issue":"4","key":"10.1016\/j.dld.2018.04.020_bib0010","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nrmicro2974","article-title":"The gut microbiota\u2013masters of host development and physiology","volume":"11","author":"Sommer","year":"2013","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.dld.2018.04.020_bib0015","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3389\/fmicb.2011.00180","article-title":"Gut microbiota, immunity, and disease: a complex relationship","volume":"2","author":"Kosiewicz","year":"2011","journal-title":"Front Microbiol"},{"key":"10.1016\/j.dld.2018.04.020_bib0020","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2016.02.028","article-title":"The intestinal microenvironment and functional gastrointestinal disorders","author":"Barbara","year":"2016","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.dld.2018.04.020_bib0025","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1056\/NEJMe1000850","article-title":"Gut flora and hepatic encephalopathy in patients with cirrhosis","volume":"362","author":"Riordan","year":"2010","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.dld.2018.04.020_bib0030","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1136\/gut.2006.108712","article-title":"Small intestinal bacterial overgrowth in patients with irritable bowel syndrome","volume":"56","author":"Posserud","year":"2007","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.dld.2018.04.020_bib0035","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s10620-012-2033-7","article-title":"The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome","volume":"57","author":"Pyleris","year":"2012","journal-title":"Dig Dis Sci"},{"issue":"8","key":"10.1016\/j.dld.2018.04.020_bib0040","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nrgastro.2014.40","article-title":"A role for the gut microbiota in IBS","volume":"11","author":"Collins","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.dld.2018.04.020_bib0045","first-page":"127","article-title":"Gut microbiota, inflammation and symptomatic diverticular disease. New insights into an old and neglected disorder","volume":"19","author":"Quigley","year":"2010","journal-title":"J Gastrointestin Liver Dis"},{"issue":"4","key":"10.1016\/j.dld.2018.04.020_bib0050","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/DCR.0000000000000078","article-title":"A hypothesis: important role for gut microbiota in the etiopathogenesis of diverticular disease","volume":"57","author":"Daniels","year":"2014","journal-title":"Dis Colon Rectum"},{"issue":"3","key":"10.1016\/j.dld.2018.04.020_bib0055","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1152\/physrev.00045.2009","article-title":"Gut microbiota in health and disease","volume":"90","author":"Sekirov","year":"2010","journal-title":"Physiol Rev"},{"issue":"7415","key":"10.1016\/j.dld.2018.04.020_bib0060","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/nature11552","article-title":"Functional interactions between the gut microbiota and host metabolism","volume":"489","author":"Tremaroli","year":"2012","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.dld.2018.04.020_bib0065","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4161\/gmic.19320","article-title":"The role of gut microbiota in immune homeostasis and autoimmunity","volume":"3","author":"Wu","year":"2012","journal-title":"Gut microbes"},{"issue":"Suppl. 1","key":"10.1016\/j.dld.2018.04.020_bib0070","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/apt.13434","article-title":"Review article: the antimicrobial effects of rifaximin on the gut microbiota","volume":"43","author":"DuPont","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"40","key":"10.1016\/j.dld.2018.04.020_bib0075","doi-asserted-by":"crossref","first-page":"11321","DOI":"10.3748\/wjg.v21.i40.11321","article-title":"Pathological and therapeutic interactions between bacteriophages, microbes and the host in inflammatory bowel disease","volume":"21","author":"Babickova","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"4","key":"10.1016\/j.dld.2018.04.020_bib0080","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s11011-014-9507-6","article-title":"Enhancement of functional connectivity, working memory and inhibitory control on multi-modal brain MR imaging with rifaximin in cirrhosis: implications for the gut-liver-brain axis","volume":"29","author":"Ahluwalia","year":"2014","journal-title":"Metab Brain Dis"},{"issue":"7122","key":"10.1016\/j.dld.2018.04.020_bib0085","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/nature05414","article-title":"An obesity-associated gut microbiome with increased capacity for energy harvest","volume":"444","author":"Turnbaugh","year":"2006","journal-title":"Nature"},{"issue":"7346","key":"10.1016\/j.dld.2018.04.020_bib0090","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/nature09944","article-title":"Enterotypes of the human gut microbiome","volume":"473","author":"Arumugam","year":"2011","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.dld.2018.04.020_bib0095","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jaci.2014.11.012","article-title":"The gut microbiota and inflammatory noncommunicable diseases: associations and potentials for gut microbiota therapies","volume":"135","author":"West","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"12","key":"10.1016\/j.dld.2018.04.020_bib0100","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","article-title":"Rifaximin treatment in hepatic encephalopathy","volume":"362","author":"Bass","year":"2010","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.dld.2018.04.020_bib0105","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1097\/DCR.0b013e318223cb2b","article-title":"Treatment of diverticular disease of the colon and prevention of acute diverticulitis: a systematic review","volume":"54","author":"Maconi","year":"2011","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.dld.2018.04.020_bib0110","article-title":"The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review","author":"Sperber","year":"2016","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.dld.2018.04.020_bib0115","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/hep.27210","article-title":"Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the american association for the study of liver diseases and the European association for the study of the liver","volume":"60","author":"Vilstrup","year":"2014","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.dld.2018.04.020_bib0120","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/hep.21533","article-title":"Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy","volume":"45","author":"Prasad","year":"2007","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.dld.2018.04.020_bib0125","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/hep.23128","article-title":"Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test","volume":"50","author":"Bajaj","year":"2009","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.dld.2018.04.020_bib0130","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1038\/ajg.2014.264","article-title":"Covert hepatic encephalopathy is independently associated with poor survival and increased risk of hospitalization","volume":"109","author":"Patidar","year":"2014","journal-title":"Am J Gastroenterol"},{"issue":"5 Pt 2","key":"10.1016\/j.dld.2018.04.020_bib0135","doi-asserted-by":"crossref","first-page":"28S","DOI":"10.1592\/phco.30.pt2.28S","article-title":"Pharmacoeconomics of hepatic encephalopathy","volume":"30","author":"Neff","year":"2010","journal-title":"Pharmacotherapy"},{"issue":"9","key":"10.1016\/j.dld.2018.04.020_bib0140","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.cgh.2012.05.016","article-title":"In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009","volume":"10","author":"Stepanova","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.dld.2018.04.020_bib0145","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/hep.23500","article-title":"Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study","volume":"51","author":"Jepsen","year":"2010","journal-title":"Hepatology"},{"issue":"Suppl. 1","key":"10.1016\/j.dld.2018.04.020_bib0150","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/apt.13435","article-title":"Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis","volume":"43","author":"Bajaj","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"46","key":"10.1016\/j.dld.2018.04.020_bib0155","doi-asserted-by":"crossref","first-page":"6693","DOI":"10.3748\/wjg.v18.i46.6693","article-title":"Prevention and treatment of hepatic encephalopathy: focusing on gut microbiota","volume":"18","author":"Garcovich","year":"2012","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.dld.2018.04.020_bib0160","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/liv.12021","article-title":"Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications","volume":"33","author":"Bellot","year":"2013","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.dld.2018.04.020_bib0165","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1053\/j.gastro.2010.06.019","article-title":"Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis","volume":"139","author":"Arvaniti","year":"2010","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.dld.2018.04.020_bib0170","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/ajg.2013.219","article-title":"A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy","volume":"108","author":"Sharma","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"Suppl. 1","key":"10.1016\/j.dld.2018.04.020_bib0175","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/ajg.2014.187","article-title":"American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation","volume":"109","author":"Ford","year":"2014","journal-title":"Am J Gastroenterol"},{"issue":"17","key":"10.1016\/j.dld.2018.04.020_bib0180","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1056\/NEJMra1207068","article-title":"Peripheral mechanisms in irritable bowel syndrome","volume":"367","author":"Camilleri","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.dld.2018.04.020_bib0185","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1053\/j.gastro.2009.02.074","article-title":"Postinfectious irritable bowel syndrome","volume":"136","author":"Spiller","year":"2009","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.dld.2018.04.020_bib0190","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/gutjnl-2012-302167","article-title":"Intestinal microbiota in functional bowel disorders: a Rome foundation report","volume":"62","author":"Simren","year":"2013","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.dld.2018.04.020_bib0195","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1365-2982.2012.01891.x","article-title":"Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome","volume":"24","author":"Carroll","year":"2012","journal-title":"Neurogastroenterol Motil"},{"issue":"12","key":"10.1016\/j.dld.2018.04.020_bib0200","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.3748\/wjg.v10.i12.1802","article-title":"Intestinal microecology and quality of life in irritable bowel syndrome patients","volume":"10","author":"Si","year":"2004","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.dld.2018.04.020_bib0205","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1572-0241.2005.40312.x","article-title":"Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR","volume":"100","author":"Malinen","year":"2005","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.dld.2018.04.020_bib0210","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1053\/j.gastro.2013.09.046","article-title":"A diet low in FODMAPs reduces symptoms of irritable bowel syndrome","volume":"146","author":"Halmos","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2018.04.020_bib0215","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12876-014-0189-7","article-title":"Intestinal permeability\u2014a new target for disease prevention and therapy","author":"Bischoff","year":"2014","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"10.1016\/j.dld.2018.04.020_bib0220","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1053\/j.gastro.2006.11.039","article-title":"Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome","volume":"132","author":"Barbara","year":"2007","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.dld.2018.04.020_bib0225","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1053\/j.gastro.2015.01.042","article-title":"Nerve fiber outgrowth is increased in the intestinal mucosa of patients with irritable bowel syndrome","volume":"148","author":"Dothel","year":"2015","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.dld.2018.04.020_bib0230","doi-asserted-by":"crossref","first-page":"G439","DOI":"10.1152\/ajpgi.00368.2015","article-title":"Interferon-gamma is increased in the gut of patients with irritable bowel syndrome and modulates serotonin metabolism","volume":"310","author":"Barbaro","year":"2016","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"Suppl. 1","key":"10.1016\/j.dld.2018.04.020_bib0235","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/apt.13437","article-title":"Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea","volume":"43","author":"Pimentel","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.dld.2018.04.020_bib0240","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1111\/j.1572-0241.2008.01879.x","article-title":"Diverticular disease and diverticulitis","volume":"103","author":"Sheth","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.dld.2018.04.020_bib0245","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1053\/j.gastro.2008.12.054","article-title":"A population-based study of perforated diverticular disease incidence and associated mortality","volume":"136","author":"Humes","year":"2009","journal-title":"Gastroenterology"},{"issue":"11\u201312","key":"10.1016\/j.dld.2018.04.020_bib0250","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/j.1365-2036.2009.04098.x","article-title":"Diverticular disease hospital admissions are increasing, with poor outcomes in the elderly and emergency admissions","volume":"30","author":"Jeyarajah","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"9409","key":"10.1016\/j.dld.2018.04.020_bib0255","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0140-6736(04)15597-9","article-title":"Diverticular disease of the colon","volume":"363","author":"Stollman","year":"2004","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.dld.2018.04.020_bib0260","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/bjs.4277","article-title":"Origin of symptoms in diverticular disease","volume":"90","author":"Simpson","year":"2003","journal-title":"Br J Surg"},{"issue":"Suppl. 1","key":"10.1016\/j.dld.2018.04.020_bib0265","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1097\/MCG.0000000000000626","article-title":"Assessment of fecal microbiota and fecal metabolome in symptomatic uncomplicated diverticular disease of the colon","volume":"50","author":"Tursi","year":"2016","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.dld.2018.04.020_bib0270","article-title":"Gut microbiota, metabolome and immune signatures in patients with uncomplicated diverticular disease","author":"Barbara","year":"2016","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.dld.2018.04.020_bib0275","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1053\/j.gastro.2012.12.030","article-title":"Heritability and familial aggregation of diverticular disease: a population-based study of twins and siblings","volume":"144","author":"Strate","year":"2013","journal-title":"Gastroenterology"},{"issue":"Suppl. 1","key":"10.1016\/j.dld.2018.04.020_bib0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/apt.13406","article-title":"Introduction: understanding mechanisms of the actions of rifaximin in selected gastrointestinal diseases","volume":"43","author":"DuPont","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl. 1","key":"10.1016\/j.dld.2018.04.020_bib0285","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/apt.13436","article-title":"Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases","volume":"43","author":"Sartor","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.dld.2018.04.020_bib0290","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11011-013-9383-5","article-title":"Antibiotics for the treatment of hepatic encephalopathy","volume":"28","author":"Patidar","year":"2013","journal-title":"Metab Brain Dis"},{"issue":"43","key":"10.1016\/j.dld.2018.04.020_bib0295","doi-asserted-by":"crossref","first-page":"7577","DOI":"10.3748\/wjg.v19.i43.7577","article-title":"Clostridium difficile and inflammatory bowel disease: role in pathogenesis and implications in treatment","volume":"19","author":"Nitzan","year":"2013","journal-title":"World J Gastroenterol"},{"issue":"12","key":"10.1016\/j.dld.2018.04.020_bib0300","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1007\/BF02234471","article-title":"Intracolonic use of vancomycin for treatment of clostridium difficile colitis in a patient with a diverted colon: report of a case","volume":"44","author":"Nathanson","year":"2001","journal-title":"Dis Colon Rectum"},{"issue":"7","key":"10.1016\/j.dld.2018.04.020_bib0305","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1185\/03007995.2014.908278","article-title":"Emerging role of probiotics and antimicrobials in the management of irritable bowel syndrome","volume":"30","author":"Cash","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.dld.2018.04.020_bib0310","first-page":"159","article-title":"Profile of rifaximin and its potential in the treatment of irritable bowel syndrome","volume":"8","author":"Iorio","year":"2015","journal-title":"Clin Exp Gastroenterol"},{"issue":"3","key":"10.1016\/j.dld.2018.04.020_bib0315","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1128\/AAC.01108-07","article-title":"Systemic pharmacokinetics of rifaximin in volunteers with shigellosis","volume":"52","author":"Taylor","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.dld.2018.04.020_bib0320","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1128\/AAC.44.8.2205-2206.2000","article-title":"In vitro activity and fecal concentration of rifaximin after oral administration","volume":"44","author":"Jiang","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.dld.2018.04.020_bib0325","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1128\/AAC.00161-10","article-title":"Bile acids improve the antimicrobial effect of rifaximin","volume":"54","author":"Darkoh","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"43","key":"10.1016\/j.dld.2018.04.020_bib0330","doi-asserted-by":"crossref","first-page":"12322","DOI":"10.3748\/wjg.v21.i43.12322","article-title":"Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications","volume":"21","author":"Ponziani","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.dld.2018.04.020_bib0335","first-page":"1676","article-title":"The effect of rifaximin on gut flora and Staphylococcus resistance","volume":"58","author":"Kim","year":"2013","journal-title":"Dis Colon Rectum"},{"issue":"2","key":"10.1016\/j.dld.2018.04.020_bib0340","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1053\/j.gastro.2013.10.026","article-title":"Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats","volume":"146","author":"Xu","year":"2014","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.dld.2018.04.020_bib0345","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1093\/jac\/dkq345","article-title":"Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system","volume":"65","author":"Maccaferri","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.dld.2018.04.020_bib0350","doi-asserted-by":"crossref","first-page":"571","DOI":"10.4161\/gmic.32130","article-title":"Rifaximin, gut microbes and mucosal inflammation: unraveling a complex relationship","volume":"5","author":"Gao","year":"2014","journal-title":"Gut microbes"},{"issue":"3","key":"10.1016\/j.dld.2018.04.020_bib0355","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ijantimicag.2009.11.013","article-title":"Rifaximin-induced alteration of virulence of diarrhoea-producing Escherichia coli and Shigella sonnei","volume":"35","author":"Jiang","year":"2010","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1016\/j.dld.2018.04.020_bib0360","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1128\/AAC.00691-09","article-title":"Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles","volume":"54","author":"Brown","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.dld.2018.04.020_bib0365","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1016\/j.jceh.2014.04.004","article-title":"Management of overt hepatic encephalopathy","volume":"5","author":"Sharma","year":"2015","journal-title":"J Clin Exp Hepatol"},{"issue":"6","key":"10.1016\/j.dld.2018.04.020_bib0370","first-page":"542","article-title":"Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy","volume":"39","author":"Strauss","year":"1992","journal-title":"Hepato-gastroenterology"},{"issue":"6","key":"10.1016\/j.dld.2018.04.020_bib0375","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/BF01308097","article-title":"Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy: a randomized clinical study","volume":"26","author":"Orlandi","year":"1981","journal-title":"Dig Dis Sci"},{"issue":"5","key":"10.1016\/j.dld.2018.04.020_bib0380","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/BF01072921","article-title":"Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy. A controlled: double-blind clinical trial","volume":"23","author":"Atterbury","year":"1978","journal-title":"Am J Dig Dis"},{"issue":"4 Pt 1","key":"10.1016\/j.dld.2018.04.020_bib0385","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0016-5085(77)80135-2","article-title":"Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy: a double blind controlled trial","volume":"72","author":"Conn","year":"1977","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.dld.2018.04.020_bib0390","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/apt.13122","article-title":"Systematic review with network meta-analysis: the comparative effectiveness and safety of interventions in patients with overt hepatic encephalopathy","volume":"41","author":"Zhu","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.dld.2018.04.020_bib0395","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/gut.31.6.702","article-title":"Successful use of vancomycin hydrochloride in the treatment of lactulose resistant chronic hepatic encephalopathy","volume":"31","author":"Tarao","year":"1990","journal-title":"Gut"},{"key":"10.1016\/j.dld.2018.04.020_bib0400","first-page":"331","article-title":"Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy","volume":"8","author":"Kimer","year":"2014","journal-title":"Patient Prefer Adherence"},{"issue":"8","key":"10.1016\/j.dld.2018.04.020_bib0405","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.cgh.2013.12.021","article-title":"Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy","volume":"12","author":"Mullen","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.dld.2018.04.020_bib0410","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/apt.12993","article-title":"Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis","volume":"41","author":"Bajaj","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.dld.2018.04.020_bib0415","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1185\/03007999309111539","article-title":"Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy","volume":"13","author":"Bucci","year":"1993","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"10.1016\/j.dld.2018.04.020_bib0420","first-page":"403","article-title":"Rifaximine versus neomycin in the treatment of portosystemic encephalopathy","volume":"23","author":"Di Piazza","year":"1991","journal-title":"Ital J Gastroenterol"},{"issue":"11","key":"10.1016\/j.dld.2018.04.020_bib0425","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1097\/MEG.0b013e328302f470","article-title":"Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis","volume":"20","author":"Jiang","year":"2008","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.dld.2018.04.020_bib0430","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0168-8278(02)00350-1","article-title":"Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial","volume":"38","author":"Mas","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2018.04.020_bib0435","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/HMER.S11988","article-title":"Rifaximin in the treatment of hepatic encephalopathy","volume":"3","author":"Iadevaia","year":"2011","journal-title":"Hepat Med Evid Res"},{"key":"10.1016\/j.dld.2018.04.020_bib0440","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060042","article-title":"Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy","author":"Bajaj","year":"2013","journal-title":"PLoS One"},{"issue":"September (9)","key":"10.1016\/j.dld.2018.04.020_bib0445","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/ajg.2013.219","article-title":"A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy","volume":"108","author":"Sharma","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"June (3)","key":"10.1016\/j.dld.2018.04.020_bib0450","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3349\/ymj.2005.46.3.399","article-title":"Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study","volume":"46","author":"Paik","year":"2005","journal-title":"Yonsei Med J"},{"issue":"7","key":"10.1016\/j.dld.2018.04.020_bib0455","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.cgh.2012.02.025","article-title":"Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites","volume":"10","author":"Kalambokis","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.dld.2018.04.020_bib0460","doi-asserted-by":"crossref","first-page":"557","DOI":"10.7326\/0003-4819-145-8-200610170-00004","article-title":"The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial","volume":"145","author":"Pimentel","year":"2006","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.dld.2018.04.020_bib0465","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10620-007-9839-8","article-title":"Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS","volume":"53","author":"Yang","year":"2008","journal-title":"Dig Dis Sci"},{"issue":"2","key":"10.1016\/j.dld.2018.04.020_bib0470","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1572-0241.2006.00458.x","article-title":"A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence","volume":"101","author":"Sharara","year":"2006","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.dld.2018.04.020_bib0475","first-page":"89","article-title":"Small intestine bacterial overgrowth in irritable bowel syndrome: a retrospective study with rifaximin","volume":"52","author":"Cuoco","year":"2006","journal-title":"Minerva Gastroenterol Dietol"},{"issue":"1","key":"10.1016\/j.dld.2018.04.020_bib0480","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1004409","article-title":"Rifaximin therapy for patients with irritable bowel syndrome without constipation","volume":"364","author":"Pimentel","year":"2011","journal-title":"N Engl J Med"},{"issue":"11\u201312","key":"10.1016\/j.dld.2018.04.020_bib0485","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/apt.12087","article-title":"Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3\u202fmonths","volume":"36","author":"Meyrat","year":"2012","journal-title":"Aliment. Pharmacol. Ther"},{"issue":"10","key":"10.1016\/j.dld.2018.04.020_bib0490","first-page":"1314","article-title":"Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome","volume":"17","author":"Scarpellini","year":"2013","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"1","key":"10.1016\/j.dld.2018.04.020_bib0495","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/ajg.2011.355","article-title":"The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis","volume":"107","author":"Menees","year":"2012","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.dld.2018.04.020_bib0500","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.amjmed.2011.08.026","article-title":"Evaluation of harm in the pharmacotherapy of irritable bowel syndrome","volume":"125","author":"Shah","year":"2012","journal-title":"The American journal of medicine"},{"key":"10.1016\/j.dld.2018.04.020_bib0505","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2147\/CEG.S89999","article-title":"Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach","volume":"8","author":"Soldi","year":"2015","journal-title":"Clin Exp Gastroenterol"},{"issue":"6","key":"10.1016\/j.dld.2018.04.020_bib0510","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1053\/j.gastro.2016.08.003","article-title":"Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome","volume":"151","author":"Lembo","year":"2016","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.dld.2018.04.020_bib0515","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1080\/14740338.2016.1186639","article-title":"Rifaximin for the treatment of irritable bowel syndrome \u2013 a drug safety evaluation","volume":"15","author":"Ponziani","year":"2016","journal-title":"Expert Opin Drug Saf"},{"issue":"10","key":"10.1016\/j.dld.2018.04.020_bib0520","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/apt.12735","article-title":"Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials","volume":"39","author":"Schoenfeld","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl. 1","key":"10.1016\/j.dld.2018.04.020_bib0525","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000081990","article-title":"Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential","volume":"51","author":"Scarpignato","year":"2005","journal-title":"Chemotherapy"},{"issue":"6","key":"10.1016\/j.dld.2018.04.020_bib0530","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/apt.13322","article-title":"Review article: the pathophysiology and medical management of diverticulosis and diverticular disease of the colon","volume":"42","author":"Tursi","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"April (7)","key":"10.1016\/j.dld.2018.04.020_bib0535","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1365-2036.2007.03266.x","article-title":"Interaction between rifaximin and dietary fibre in patients with diverticular disease","volume":"25","author":"D'Inc\u00e0","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.dld.2018.04.020_bib0540","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/1756283X11412820","article-title":"Management of colonic diverticular disease with poorly absorbed antibiotics and other therapies","volume":"4","author":"Sopena","year":"2011","journal-title":"Therap Adv Gastroenterol"},{"issue":"3","key":"10.1016\/j.dld.2018.04.020_bib0545","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/1756283X13478679","article-title":"New strategies for the management of diverticular disease: insights for the clinician","volume":"6","author":"Boynton","year":"2013","journal-title":"Therap Adv Gastroenterol"},{"issue":"8","key":"10.1016\/j.dld.2018.04.020_bib0550","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/j.1365-2036.2011.04606.x","article-title":"Meta-analysis: long-term therapy with rifaximin in the management of uncomplicated diverticular disease","volume":"33","author":"Bianchi","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"1\u20132","key":"10.1016\/j.dld.2018.04.020_bib0555","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00508-013-0447-7","article-title":"Non-interventional study evaluating efficacy and tolerability of rifaximin for treatment of uncomplicated diverticular disease","volume":"126","author":"Stallinger","year":"2014","journal-title":"Wien Klin Wochenschr"},{"issue":"2","key":"10.1016\/j.dld.2018.04.020_bib0560","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3748\/wjg.v13.i2.264","article-title":"Efficacy of long term cyclic administration of the poorly absorbed antibiotic Rifaximin in symptomatic: uncomplicated colonic diverticular disease","volume":"13","author":"Colecchia","year":"2007","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.dld.2018.04.020_bib0565","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00384-002-0396-5","article-title":"Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon","volume":"18","author":"Latella","year":"2003","journal-title":"Int J Colorectal Dis"},{"issue":"8","key":"10.1016\/j.dld.2018.04.020_bib0570","first-page":"452","article-title":"Efficacy of rifaximin on symptoms of uncomplicated diverticular disease of the colon: a pilot multicentre open trial. Diverticular Disease Study Group","volume":"24","author":"Papi","year":"1992","journal-title":"Ital J Gastroenterol"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865818307175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865818307175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T10:10:00Z","timestamp":1604225400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865818307175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":114,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S1590865818307175"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2018.04.020","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2018.04.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}